Great news this morning for NOVA that should help push its momentum towards first resistance level in the next days and could definitely breakthrough if volume continues up from this news.
The U.S. Food and Drug Administration has approved Nova Mentis Life Science Corp.'s proprietary psilocybin drug orphan drug application to treat patients with fragile X syndrome (FXS), the most common inherited cause of autism spectrum disorder (ASD).
This is a small biotech, so do your DD and analysis.
The U.S. Food and Drug Administration has approved Nova Mentis Life Science Corp.'s proprietary psilocybin drug orphan drug application to treat patients with fragile X syndrome (FXS), the most common inherited cause of autism spectrum disorder (ASD).
This is a small biotech, so do your DD and analysis.